Navigation Links
Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management
Date:4/11/2008

KENILWORTH, N.J., April 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) announced today a new governance action intended to strengthen the alignment of executives with the interests of shareholders.

"We are expanding the stock retention guidelines, which we believe are now among the strongest in our industry, for the Executive Management Team (including the five highest-paid executives)," said Hans W. Becherer, Chairman of the Compensation Committee of the Board of Directors.

Key elements of the policy are as follows:

-- Going forward, the executives are required to hold shares acquired upon

the exercise of stock options for two years (not including shares used

to pay the exercise price and tax withholding on the exercise).

-- Existing stock ownership guidelines continue in effect. Those

guidelines require the CEO to hold eight times salary in stock and

other senior executives (including the executive vice presidents) to

hold four times salary in stock.

"Schering-Plough executive compensation policies tie a significant percentage of compensation to performance. Further, a significant portion of total executive compensation is already paid in stock (rather than cash) to align management with shareholders. The policy we are announcing today further strengthens that alignment with shareholders, at a time when our industry and our company are under increasing challenge," said Becherer.

"The actions we are announcing today further strengthen our company in a challenging environment, as we continue with confidence to drive toward our goal of long-term high performance," said Fred Hassan, chairman and CEO.

Schering-Plough is an
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Schering-Plough to Webcast Presentation by CEO Fred Hassan at Lehman Brothers Eleventh Annual Global Healthcare Conference
2. Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain
3. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
4. Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough
5. Schering-Plough CEO to Buy $2 Million in Common Shares
6. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
7. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
10. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
11. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Lack of happiness hormone serotonin in the brain causes impaired maternal behavior in mice 8972 1Energy saving method checks refrigerant level in air conditioners 8970 1Energy saving method checks refrigerant level in air conditioners 8970 2How to text message and avoid pain 8968 1How to text message and avoid pain 8968 2